Coriolus mushroom

Coriolus Mushroom (Trametes versicolor): A Comprehensive Reference

1. Identity, Nomenclature, and Natural Source

Scientific nomenclature. The organism formerly classified as Coriolus versicolor (L.) Quél. is now accepted under the current scientific name Trametes versicolor (L.) Lloyd, belonging to the family Polyporaceae. Additional historical synonyms include Polyporus versicolor and Polystictus versicolor. All of these names refer to the same fungal species; the former name Coriolus versicolor remains prevalent in the clinical and supplementation literature and in most studies predating modern mycological reclassification.

Common names. Its scientific epithet versicolor is Latin for "of various colors," accurately reflecting the broad spectrum of hues visible across the fruiting body. In China the mushroom has long been treasured under the name Yun Zhi, meaning "cloud fungus," and in Japan it is known as Kawaratake, meaning "mushroom by the river bank." In English-speaking countries it is most widely called turkey tail, a name that refers to its concentric rings of brown and tan, which resemble the tail feathers of a turkey.

Taxonomy and morphology. Coriolus versicolor is a mushroom of the Basidiomycetes class — fungi bearing gills or pores, the group that includes familiar edible mushrooms. The visible form is a fan-shaped mushroom with a wavy margin and colored concentric zones; the layers may be light to dark brown or gray and resemble a turkey tail. The fruit bodies typically grow in compact rosette layers and are extremely thin with a leathery texture; the caps have tiny fuzzy hairs and rows of concentric lines that form distinct color zones, creating unique patterns distinct to each organism.

Habitat and distribution. Coriolus versicolor is an obligate aerobe commonly found year-round on dead logs, stumps, tree trunks, and branches. It occurs throughout the wooded temperate zones of Asia, Europe, and North America and may be the most common shelf fungus in the Northern Hemisphere.

Taxonomic caution. There are many other species of Trametes, some of which are difficult to distinguish from turkey tail; internal transcribed spacer sequences alone have been found inadequate to distinguish turkey tail from other species of Trametes, so additional molecular characters are required. This is a practically relevant point for supplement quality and authentication.

Common preparations and dosage forms. Coriolus is used not as food but as medicine, ingested as capsules, as an extract, or as a tea. Hot-water extracts of the whole fruiting body have been used in traditional Chinese medicine since historic times. Two commercial extracts have been used clinically in the Far East — polysaccharide-Krestin (PSK) and polysaccharopeptide (PSP) — both of which are orally bioavailable extracts from the cultured mycelium of the fungus. The mushroom's active medicinal components — protein-bound polysaccharides — are found in both the fruiting body and the mycelium (the vegetative stage), although the concentration of the polysaccharide component is significantly higher when extracted before the mushroom reaches the fruiting body stage. Extracts of turkey tail or the mushroom itself are commonly marketed as a dietary supplement, and quality can vary due to inconsistent processing and labeling.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine (TCM)

The medicinal use of Trametes versicolor spans millennia, with documented applications in traditional Chinese medicine dating back over 2,000 years. Known in TCM as Yun Zhi (云芝), meaning "cloud mushroom," it has been revered for its ability to strengthen the immune system, promote longevity, and support overall vitality. Ancient Chinese medical texts describe its use for "clearing dampness," "strengthening the spleen," and "supporting righteous qi" — concepts that align with modern understanding of its immunomodulatory and digestive health effects. In China, it was used to combat pulmonary or gastrointestinal complaints, or to enhance overall wellness and vitality.

Known as yun zhi in traditional Chinese medicine, Trametes versicolor was utilized for over 2,000 years to promote vitality, treat infections, and support respiratory health, often prepared as a tea or decoction to clear phlegm and dampness from the lungs. Historical texts such as the Ben Cao Gang Mu from the 16th century document its role in enhancing energy levels and managing pulmonary disorders, reflecting its longstanding status as an immunotonic and adaptogenic agent. It has also been documented in major texts such as the Compendium of Materia Medica by Li Shizhen (1578), a renowned Chinese herbalist and pharmacologist.

2.2 Japanese Traditional Medicine

In Japan, referred to as kawaratake, it similarly served in folk medicine, integrated into daily tonics for overall wellbeing before modern pharmacological developments. In Japan, turkey tail has also been used to strengthen the immune system when given with standard cancer treatment, a practice that eventually led to the pharmaceutical development of PSK (see Section 4). In the 1970s, Japanese researchers isolated PSK (polysaccharide-K), a compound later approved as an official adjunct in cancer therapy.

2.3 Native American and Other Traditional Uses

Among Native American communities, particularly the Lakota, infusions of Trametes versicolor were employed in pre-20th-century healing practices to address respiratory infections and urinary tract issues through boiled decoctions, leveraging its purported anti-inflammatory properties.

2.4 Cultural Significance

In China, the swirling Cloud Mushroom was used as a motif on the breastplate badges of Chinese generals to symbolize rank and prestige. Ancient Chinese formulations of Coriolus versicolor have long been believed to generally promote health, strength, and longevity.

3. Key Constituents and Active Compounds

3.1 Polysaccharopeptides: PSK and PSP

The two most intensively studied and commercially significant compounds from Coriolus versicolor are the polysaccharopeptides PSK and PSP. The bioactive components of CV extracts include two polysaccharopeptides derived from two different strains of CV: COV-1 (PSP), most commonly used in China, and CM-101 (polysaccharide krestin, PSK), used in Japan. Both molecules are approximately 100 kDa, with respective polysaccharide-to-peptide balances of 90–10% in PSP and 60–40% in PSK.

PSK, also known as polysaccharide K or Krestin, is a protein-bound polysaccharide (or "proteoglycan") that has been used in Japan for more than 30 years as adjunctive immunotherapy for a variety of cancer types. PSK was first isolated in 1971 from the mushroom Coriolus versicolor, and its structure consists of a polypeptide moiety to which polysaccharide β-d-glucan chains are attached; approximately 62% of the molecule is polysaccharide and 38% is protein.

PSK (or Krestin®) was developed in Japan in the 1960s and is a soluble protein-bound polysaccharide derived from the CM-101 strain of the fungus. The primary polysaccharide in turkey tail is β-glucan. PSP's polysaccharide moiety contains a β-(1→3)-d-glucan.

Earlier studies established the distinctive features of these two polysaccharides: PSK contains fucose, while PSP contains rhamnose and arabinose. Analysis of the polysaccharide moiety of PSP showed the predominance of 1→4, 1→2 and 1→3 glucose linkages (molar ratio 3:1:2), together with small amounts of other sugar linkages. The peptide moiety of PSP contains 18 different amino acids, with aspartic and glutamic acid residues being most predominant. Both PSK and PSP polymers are soluble in water.

3.2 Phenolic Compounds

HPLC–MS/MS-based studies have identified 38 phenolic compounds in the fruiting body of C. versicolor of European origin, belonging to the flavonoid classes (flavones, flavonols, flavanone, flavanols, biflavonoids, isoflavonoids) and hydroxy cinnamic acids. The water extracts were shown to contain considerable amounts of baicalein (21.60 µg/g dry weight), baicalin (10.7), quercetin (31.20), isorhamnetin (14.60), catechin (17.20), amentoflavone (17.20), p-hydroxybenzoic acid (141.00), and cyclohexanecarboxylic acid (80.40). The biological activities of the water extracts of C. versicolor, especially in the antioxidant area, must therefore account for the cumulative effects of these phenolic compounds.

3.3 Sterols, Triterpenoids, and Other Constituents

Turkey tail (mycelium and fruiting body) contains numerous bioactive compounds, including polysaccharides, lipids, triterpenoids, and phytosterols. It has been reported to contain more than 20 different compounds including organic acids, triterpenoids, alkaloids, steroids, proteins, and polysaccharides. C. versicolor also provides ergosterol (a precursor of vitamin D2), phytosterols such as lanosterol, fungisterol, and beta-sitosterol, as well as Tramesan (a pro-antioxidant glycan), lecithins, triterpenes, phenols, B vitamins, minerals, and amino acids.

4. Mechanisms of Action

4.1 Immunomodulation

Recent studies indicate immunostimulant and antitumor properties for which the proteoglycan constituents (PSK and PSP) are responsible. PSP promotes immune responses via induction of immunoglobulin production and engagement of various pattern-recognition molecules. A well-established mechanism of the anti-cancer effect of C. versicolor is via immunostimulant action, evidenced by the ability to increase the production of cytokines such as IL-12, which is Th1-related.

PSK and PSP have been shown to modulate innate and adaptive immunity — including increased activity of natural killer (NK) cells, improved CD4+/CD8+ ratios, and enhancement of antigen presentation — which is hypothesized to aid host anti-tumor surveillance when combined with conventional therapy. The immune effects are mediated through the mushroom's stimulation of innate immune cells, such as monocytes, natural killer cells, and dendritic cells. Mushrooms such as Coriolus versicolor increase the activity of lymphocytes — B-cells, T-cells, and especially natural killer (NK) cells. B-cells produce antibodies, whereas T-cells and NK cells destroy virally or bacterially infected cells and cancerous cells.

PSK has also been shown to mediate dendritic cell and T cell activation via TLR-2 signaling. Increased cytokine and reactive oxygen species (ROS) production and NF-κB activation have been reported in animal models. Through an IL-10-dependent mechanism, enhancement of cytokine production associated with T helper cells (Th2 and Th17) — including IL-2, -4, -6, -10, -17A and IFN-α and -γ — was observed for a glucan product of C. versicolor in cancer-bearing mice.

4.2 Direct Antitumor Activity

C. versicolor polysaccharides, including PSP and PSK, have been shown to demonstrate anti-cancer effects in vivo following oral administration, acting both through direct cytotoxicity and through immunostimulant action. The primary bioactive constituents of T. versicolor — PSPs and PSK — have been shown to induce apoptosis, arrest the cell cycle, reduce metastasis, and enhance the efficacy of chemotherapy drugs.

PSK is a biological response modifier, acting, at least in part, by modulating host immune systems such as the activation of immune effector cells and the neutralization of transforming growth factor-beta (TGFβ) activity.

4.3 Antioxidant Activity

The antioxidant potential of Coriolus versicolor extracts has been quantified alongside other medicinal mushrooms, and its antioxidant activity is driven by phenolic content. UV and FTIR spectrophotometric analyses have revealed diverse composition of C. versicolor extract and a high content of total phenolics.

4.4 Prebiotic Activity

The polysaccharides in T. versicolor serve as substrates for beneficial bacteria in the intestinal tract, promoting the growth of health-supporting microbial populations. Research has demonstrated preferential support for beneficial bacteria such as Bifidobacterium and Lactobacillus species.

4.5 Pharmacokinetics of PSK

Available data (based mainly on animal models) indicate that PSK is rapidly absorbed and partly metabolised in the gastrointestinal tract. Peak plasma levels occur between 0.5 to 2 hours for small molecules and 4 to 24 hours for large molecules. Excretion is primarily through the lungs, with 70% excreted in expired air after 24 hours. Radiolabelled PSK or its metabolites are also excreted in the urine and faeces, with 86% excreted within 24 hours.

5. Scientific Evidence by Area of Use

5.1 Cancer — General Overview of the Clinical Evidence Base

There have been many peer-reviewed publications on T. versicolor in cancer, including 37 in vitro articles, 55 animal studies, 43 published human clinical studies, and 11 review articles in gastrointestinal, breast, and lung cancer. Although polysaccharide-K, an extract of T. versicolor, is approved in Japan as an adjuvant therapy in cancer treatment, it is not approved in the United States for treatment of cancer or any clinical condition. Products using CV extracts are currently approved as adjunct therapy in China and Japan for cancer patients already receiving chemotherapy or radiotherapy.

5.2 Gastric Cancer

Gastric cancer has been the most extensively studied indication for PSK adjuvant therapy. Studies of PSK as adjuvant therapy for gastric cancer include a randomized clinical trial in Japan conducted between 1978 and 1981 that included 751 patients who had surgery for gastric cancer. After surgery, patients received chemotherapy with or without PSK. This trial reported an impressive result showing a significant survival advantage compared with standard conventional anti-cancer agents alone — a 9% absolute reduction in 5-year mortality, equivalent to one additional patient alive for every 11 patients treated. A better 5-year survival rate in patients receiving combination treatment was also reported.

People with stomach cancer who were treated with PSK or turkey tail alongside chemotherapy showed better survival across several combined analyses of studies. In one such large trial, after five years, 79% of people in the PSK group had survived, while 72.2% of people in the control group had survived. Disease-free survival at five years was 72.2% in the PSK group versus 65.9% in controls.

Evidence strength: The gastric cancer data comes from multiple randomized controlled trials conducted primarily in Japan. These trials are generally older, conducted before modern oncology standards (including updated chemotherapy regimens), and most were conducted in East Asian populations, limiting generalizability. The results are consistently positive for the PSK adjuvant, but the evidence predates contemporary RCT design standards.

5.3 Colorectal Cancer

A Cochrane systematic review (Pilkington et al., 2022) included seven trials with 1,569 participants who were men and women with stage 2 to 4 colorectal cancer. Six studies were carried out in Japan and one in China. The authors concluded that due to the very low certainty of evidence, they were uncertain about the effect of adjunctive Coriolus on adverse events resulting from conventional chemotherapy for colorectal cancer. It was also unclear whether any adverse events were due to the chemotherapy or to the extract itself. While there was low-certainty evidence of a small effect on overall survival at five years, the influence of reduced adverse effects on this could not be determined.

People with colorectal cancer treated with PSK together with chemotherapy had a lower risk of recurrence in several studies. While there was low-certainty evidence of a small effect on overall survival at five years, the chemotherapy regimens used in assessing this outcome do not reflect current preferred practice.

Evidence strength: The Cochrane review found the overall certainty of evidence to be low to very low, due to issues with trial design, older chemotherapy comparators, and conduct limitations. The direction of effect favors PSK adjuvant therapy, but definitive conclusions cannot be drawn.

5.4 Lung Cancer

A double-blind, placebo-controlled randomized trial by Tsang et al. employed 34 patients who had completed conventional treatment for advanced non-small cell lung cancer. They showed that PSP capsules of 340 mg each, taken 3 times daily for 4 weeks, could lead to an improvement in blood leukocyte and neutrophil counts, serum IgG and IgM.

A systematic review of PSK in lung cancer indicates that PSK may improve immune parameters, reduce treatment symptoms, and positively influence some survival outcomes. In clinical trials, PSP has been used for late-stage lung cancer and as a prebiotic.

Evidence strength: Clinical evidence for lung cancer is more limited in quantity and scale than for gastric or colorectal cancer. The Tsang et al. trial was small (34 patients) and focused on immune biomarkers rather than survival. Further well-powered trials are needed.

5.5 Breast Cancer

One medicinal mushroom, T. versicolor, has been studied in phase I, II, and III randomized clinical trials in stomach, colorectal, esophageal, and breast cancer patients. Japanese and Korean clinical data provide support for the hypothesis that immunomodulation can influence the clinical course in breast cancer.

A phase I, two-center, dose escalation study was conducted to determine the maximum tolerated dose of a T. versicolor preparation when taken daily in divided doses for 6 weeks after recent completion of radiotherapy for breast cancer. Eleven participants were recruited and nine women completed the study. Each cohort was comprised of three participants given one of three doses of Tv (3, 6, or 9 grams). Nine adverse events were reported (7 mild, 1 moderate, and 1 severe), suggesting that Tv was well tolerated. Findings showed that up to 9 grams/day of a Tv preparation is safe and tolerable in women with breast cancer in the post-primary treatment setting. This Tv preparation may improve immune status in immunocompromised breast cancer patients following standard primary oncologic treatment.

The fungus, known for its immunomodulatory and cytotoxic properties, is the subject of intensive research on its potential use in breast cancer therapy. A review of eleven research articles, including cell and animal models of breast cancer, shows a complex and multifaceted mechanism of action of C. versicolor extracts and isolated components such as laccase or protein–polysaccharide complexes.

Evidence strength: Clinical evidence in breast cancer is at the phase I stage, focusing primarily on safety and tolerability. Immune biomarkers showed favorable changes, but there are no large randomized phase III trials demonstrating survival benefit in breast cancer. Preclinical data are more extensive.

5.6 Immunomodulation — General (Non-Cancer Settings)

People treated with PSP or turkey tail following conventional cancer treatment showed biomarkers of higher immune function in two small studies. Laboratory studies suggest Coriolus versicolor may have antimicrobial, antiviral, and antitumor properties. Products using CV extracts are approved as adjunct therapy in China and Japan for cancer patients already receiving chemotherapy or radiotherapy.

5.7 Gut Microbiome and Prebiotic Effects

A randomized clinical trial was conducted comparing the effects of polysaccharopeptide from Trametes versicolor to those of the antibiotic amoxicillin on the human gut microbiome in 24 healthy volunteers randomized to receive PSP, amoxicillin, or no treatment (control). PSP led to clear and consistent microbiome changes consistent with its activity as a prebiotic, and despite the diversity of the human microbiome, strong microbiome clustering among subjects was noted. The microbiomes of healthy individuals remained stable over time in the control group. The antibiotic amoxicillin altered the microbiome with disruption persisting for several weeks, while PSP from T. versicolor acted as a prebiotic to modulate human intestinal microbiome composition.

Preclinical evidence suggests that turkey tail may function as a prebiotic. A small clinical trial was also performed: twenty-two healthy volunteers were randomized to either a proprietary turkey tail extract dosed at 1,200 mg three times daily (providing 1,080 mg PSP three times daily) for 14 days, a control group, or amoxicillin 250 mg three times daily for 6 days. Use of antibiotics resulted in various disruptions in normal gut flora which persisted for 42 days after stopping amoxicillin. In the turkey tail group, the microbiome of participants also shifted during treatment, but to a separate and distinct cluster of flora.

Evidence strength: The prebiotic evidence is preliminary. The clinical trial referenced had small sample sizes (22–24 participants) and short durations. Results are promising but require replication in larger, longer-term trials. Animal and in vitro data support the general concept of prebiotic activity.

5.8 Antioxidant and Anti-inflammatory Activity

Coriolus versicolor is characterized as having antitumor, anti-inflammatory, antioxidant, antiviral, antibacterial, and immunomodulatory properties, extensively demonstrated mainly using CV extract. Extensive studies have been conducted examining antitumorigenic, immunomodulating, antioxidant, cardiovascular, hypolipidemic, detoxifying, hepatoprotective, antidiabetic, and antimicrobial properties. However, most evidence for anti-inflammatory and antioxidant activity is preclinical (in vitro and animal), and human clinical trials specifically targeting these endpoints have not been conducted.

5.9 Antimicrobial Activity

UV and FTIR spectrophotometric analyses have revealed diverse composition of C. versicolor extract and a high content of total phenolics; mushroom extracts could potentially be used to develop nutraceuticals or drugs effective against pathogenic microorganisms. This evidence remains in vitro; no human trials have directly assessed antimicrobial clinical outcomes.

6. Body Systems and Health Areas Associated with Coriolus Mushroom

• Immune system: Primary area of both traditional use and scientific investigation; PSK and PSP modulate innate and adaptive immunity via NK cells, T cells, dendritic cells, and cytokine production.
• Oncology / Cancer biology: PSK is approved in Japan as an adjuvant cancer therapy; most clinical evidence is in gastric, colorectal, and lung cancers; breast cancer is at the phase I stage.
• Gastrointestinal tract: Traditional use for digestive complaints; clinical research confirms prebiotic effects on the gut microbiome; traditional use includes gastrointestinal support.
• Respiratory system: Traditional TCM use for pulmonary disorders; some clinical evidence from lung cancer trials; traditional preparations used for respiratory infections.
• Antioxidant / oxidative stress: Phenolic constituents (quercetin, baicalein, catechin, etc.) contribute to antioxidant activity; primarily supported by in vitro evidence.
• Antimicrobial: In vitro evidence of activity against bacterial pathogens; no human clinical trials.

7. Dosage Forms and Reported Dosages

Doses of PSK most commonly used in clinical trials in cancer have been between 1 g and 3.6 g daily.

A double-blind, placebo-controlled trial for non-small cell lung cancer used PSP capsules of 340 mg each, taken 3 times daily for 4 weeks.

A phase I dose-escalation study in breast cancer gave preparations daily in divided doses for 6 weeks after radiotherapy, with three cohorts receiving 3, 6, or 9 grams per day respectively. The study concluded that up to 9 grams/day of a Tv preparation is safe and tolerable in women with breast cancer in the post-primary treatment setting.

One clinical trial investigating prebiotic effects used a proprietary turkey tail extract dosed at 1,200 mg three times daily (providing 1,080 mg PSP three times daily) for 14 days.

Turkey tail glucan products (PSP or PSK) have been safely consumed at doses of 1 g or more per day for up to 10 years in cancer patients.

Multi-year dosing at 3 g/day has been documented in cancer patients without serious toxicity.

8. Safety Considerations and Drug Interactions

8.1 General Safety Profile

A safety study of the CV biomass form investigated daily administration (2.5, 5.0, and 7.5 g/kg live weight) by gavage to both female and male albino rats. No adverse or lethal effects were observed as a consequence of the daily administration of CV biomass. Turkey tail glucan products (PSP or PSK) have been safely consumed at doses of 1 g or more per day for up to 10 years in cancer patients; research reveals little or no information regarding toxicity.

8.2 Documented Adverse Effects

Diarrhea, darkened stools, and darkened nail pigmentation have been reported. In the breast cancer phase I trial, nine adverse events were reported (7 mild, 1 moderate, and 1 severe). These were generally not treatment-limiting events.

8.3 Drug Interactions

Adverse interactions between Coriolus versicolor mushroom and herbs or drugs have not been reported, except for a potential interaction with cyclophosphamide.

8.4 Regulatory Approvals and Status

T. versicolor extract (PSK) is approved as a pharmaceutical-grade medicine in Japan and has been used for more than 30 years as a treatment for cancer. Although PSK is approved in Japan as an adjuvant therapy in cancer treatment, it is not approved in the United States for treatment of cancer or any clinical condition. In the United States, the FDA has recognized Trametes versicolor as a dietary supplement.

8.5 Product Quality Concerns

Extracts of turkey tail or the mushroom itself are commonly marketed as dietary supplements, and quality can vary due to inconsistent processing and labeling. There are many other species of Trametes, some of which are difficult to distinguish from turkey tail, raising the possibility of misidentification or adulteration in commercial products. Most commercial preparations of polysaccharopeptides use only the intracellular polymers recovered from the mushroom or submerged culture mycelium.

9. Overall Characterization of the Evidence

Coriolus versicolor (turkey tail mushroom) and its principal extracts PSK and PSP are among the most extensively studied medicinal fungi in the scientific literature. Turkey tail mushroom has a longstanding history of traditional medicinal use and contains a variety of bioactive compounds, the best known of which is the polysaccharide β-glucan. Turkey tail is also the source of the protein-bound β-glucan compounds polysaccharide-K and polysaccharopeptide. The medicinal effects of turkey tail and its extracts have been studied both preclinically and clinically, including studies on immunomodulatory, antioxidative, prebiotic, and anticancer effects. The bulk of the clinical data comes from trials in people with cancer.

The strongest evidence exists for PSK as an adjuvant to chemotherapy in gastric and colorectal cancer, primarily from Japanese randomized controlled trials. However, the 2022 Cochrane systematic review concluded that the overall certainty of evidence for colorectal cancer is low to very low, largely because trial methodology is older, comparator chemotherapy regimens are outdated, and blinding was inconsistent. There are many areas where further clinical research on turkey tail mushroom remains to be conducted. For non-cancer indications — including prebiotic, antioxidant, and antimicrobial effects — evidence is largely preclinical, with only small and preliminary human studies available.

References

• Habtemariam S. Trametes versicolor (Synn. Coriolus versicolor) Polysaccharides in Cancer Therapy: Targets and Efficacy. Biomedicines. 2020;8(5):135. PMC7277906.
• Eliza WL et al. Immunomodulatory Properties of Coriolus versicolor: The Role of Polysaccharopeptide. Frontiers in Immunology. 2017. PMC5592279.
• National Cancer Institute (NCI). Medicinal Mushrooms (PDQ®) — Health Professional Version. Cancer.gov.
• NCI PDQ Cancer Information Summaries. Medicinal Mushrooms (PDQ®). NCBI Bookshelf. NBK424937.
• Pilkington K, Wieland LS, Teng L, et al. Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. Cochrane Database of Systematic Reviews. 2022;11:CD012053.
• Pilkington K et al. Cochrane Review — Coriolus (Trametes) versicolor mushroom for colorectal cancer. PMC9707730.
• Lucius K. The Medicinal Mushroom Trametes versicolor: Reviewing Preclinical and Clinical Evidence. Integrative Medicine Reports. 2026.
• Fritz H, Kennedy DA, Ishii M, et al. Polysaccharide K and Coriolus versicolor Extracts for Lung Cancer: A Systematic Review. Integrative Cancer Therapies. 2015;14(3):201–11.
• Standish LJ et al. Trametes versicolor Mushroom Immune Therapy in Breast Cancer. PMC2845472.
• Torkelson CJ, Sweet E, Martzen MR, et al. Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer. ISRN Oncology. 2012;2012:251632.
• Pallav K, Dowd SE, Villafuerte J, et al. Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial. Gut Microbes. 2014;5:458–467. PMID: 25006989.
• Safety assessment of Coriolus versicolor biomass as a food supplement. PMC4788765.
• Zhong L et al. Coriolus Versicolor and Ganoderma Lucidum Related Natural Products as an Adjunct Therapy for Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology. 2019.
• Jędrzejewski T et al. COVID-19 and Cancer Diseases — The Potential of Coriolus versicolor Mushroom to Combat Global Health Challenges. Int J Mol Sci. 2023;24(5):4864. PMID: 36902290.
• Bai M et al. Polysaccharides from Trametes versicolor as a Potential Prebiotic to Improve the Gut Microbiota in High-Fat Diet Mice. Microorganisms. 2024;12:1654. PMC11356736.
• Exploring the Anticancer Potential of Coriolus versicolor in Breast Cancer: A Review. Cancers. 2025;47(10):808.
• The Antibacterial Activity of Coriolus versicolor Methanol Extract. PMC4972825.
• CancerNetwork. Coriolus versicolor monograph.
• Drugs.com. Turkey Tail Uses, Benefits & Dosage. Medically reviewed February 2026.
• Cochrane. Coriolus versicolor mushroom in colorectal cancer — plain language summary.